Beijing-based Tsingke Biotech, a pioneer in molecular manufacturing, showcased its AI-driven biomanufacturing ecosystem at the 2025 Festival of Biologics in Basel. The company demonstrated how automation, digital design, and scalable synthesis are bridging the gap between laboratory research and industrial-scale biologics production.
Tsingke’s integrated platform connects gene and RNA design with antibody discovery and GMP-grade production — enabling early manufacturability validation, data-driven antibody engineering, and multimolecular integration across ADCs, PROTACs, and AOCs.
With ISO 13485–certified facilities and automation-driven processes, Tsingke continues to redefine precision biomanufacturing, supporting global research and therapeutic innovation through end-to-end molecular design and production capabilities.
Image one-liner:
